Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the stock in a transaction on Wednesday, May 17th. The stock was acquired at an average cost of $3.73 per share, for a total transaction of $10,257.50. Following the completion of the acquisition, the director now owns 2,750 shares of the […]
Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Rating) Director Joseph Truitt purchased 2,750 shares of the business’s stock in a transaction on Wednesday, May 17th. The stock was acquired at an average price of $3.73 per share, with a total value of $10,257.50. Following the purchase, the director now directly owns 2,750 shares in the company, […]
Plus, EY picked 30 local finalists as Entrepreneurs Of The Year, PACT named a Legend Enterprise awardee, and Comcast's RISE program is open for applications.
Take note of these November and December announcements, including a $65 Series A for Penn gene-editing spinout iECURE. Plus, the Center for Diagnostics Discovery is launching in Horsham.